Last reviewed · How we verify
Azienda Ospedaliera Universitaria Senese — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Dolutegravir/lamivudine/abacavir | Dolutegravir/lamivudine/abacavir | phase 3 | Antiretroviral combination (INSTI + NRTI backbone) | HIV integrase, HIV reverse transcriptase | Infectious Disease / Virology |
Therapeutic area mix
- Infectious Disease / Virology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Azienda Ospedaliera Universitaria Senese:
- Azienda Ospedaliera Universitaria Senese pipeline updates — RSS
- Azienda Ospedaliera Universitaria Senese pipeline updates — Atom
- Azienda Ospedaliera Universitaria Senese pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Ospedaliera Universitaria Senese — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-universitaria-senese. Accessed 2026-05-17.